This article is more than 5 years old. Information may no longer be current.

Subgroups in VIEW studies maintained visual improvements with less dosing frequency

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

After a year of fixed treatment in the VIEW studies, 50% of patients with neovascular age-related macular degeneration who received 2 mg of intravitreal aflibercept could be extended to dosing every 12 weeks during the second year compared with 43% of patients who received 0.5 mg of ranibizumab, according to a presentation at the Macula Society annual meeting in Singapore.

The subgroup of patients that received dosing every 12 weeks during year 2 as opposed to more frequent dosing had smaller choroidal neovascularization area and lesion size, a lower proportion of occult lesions and lower central retinal thickness, David S. Boyer, MD, said in a presentation of a subanalysis of the VIEW studies.

Additionally, a higher proportion of patients who were dosed every 12 weeks had fluid absent on time domain OCT compared with those who were dosed more frequently.

Visual and anatomic improvements seen at week 52 were mostly maintained in patients in the every 12 weeks or greater dosing subgroup and the more frequent dosing group, the presentation said. – by Robert Linnehan

Reference:

Boyer DS. Outcomes in patients with neovascular age-related macular degeneration based on dosing intervals in the second year of the VIEW studies. Presented at: Macula Society annual meeting; June 7-10, 2017; Singapore.

Disclosure: Boyer reports having relevant financial disclosures with Allergan, Acucela, Aerpio, Allegro, Alcon, Bausch + Lomb, Bayer, Genentech, Novartis, Regeneron, Roche, Ohr, Ora, TLC, Occunes, Ocuvue, Optos, DigiSight, ThromboGenics, CoDa, BioMotiv, Boehringer Ingelheim, Foresight, GenSight, Glaukos, GlaxoSmithKline, Regenxbio, Regulus, Shire, Santen and Sun.